LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.

Abstract:

BACKGROUND:LMO2 is highly expressed at the most immature stages of lymphopoiesis. In T-lymphocytes, aberrant LMO2 expression beyond those stages leads to T-cell acute lymphoblastic leukemia, while in B cells LMO2 is also expressed in germinal center lymphocytes and diffuse large B-cell lymphomas, where it predicts better clinical outcome. The implication of LMO2 in B-cell acute lymphoblastic leukemia must still be explored. DESIGN AND METHODS:We measured LMO2 expression by real time RT-PCR in 247 acute lymphoblastic leukemia patient samples with cytogenetic data (144 of them also with survival and immunophenotypical data) and in normal hematopoietic and lymphoid cells. RESULTS:B-cell acute lymphoblastic leukemia cases expressed variable levels of LMO2 depending on immunophenotypical and cytogenetic features. Thus, the most immature subtype, pro-B cells, displayed three-fold higher LMO2 expression than pre-B cells, common-CD10+ or mature subtypes. Additionally, cases with TEL-AML1 or MLL rearrangements exhibited two-fold higher LMO2 expression compared to cases with BCR-ABL rearrangements or hyperdyploid karyotype. Clinically, high LMO2 expression correlated with better overall survival in adult patients (5-year survival rate 64.8% (42.5%-87.1%) vs. 25.8% (10.9%-40.7%), P= 0.001) and constituted a favorable independent prognostic factor in B-ALL with normal karyotype: 5-year survival rate 80.3% (66.4%-94.2%) vs. 63.0% (46.1%-79.9%) (P= 0.043). CONCLUSIONS:Our data indicate that LMO2 expression depends on the molecular features and the differentiation stage of B-cell acute lymphoblastic leukemia cells. Furthermore, assessment of LMO2 expression in adult patients with a normal karyotype, a group which lacks molecular prognostic factors, could be of clinical relevance.

journal_name

Haematologica

journal_title

Haematologica

authors

Malumbres R,Fresquet V,Roman-Gomez J,Bobadilla M,Robles EF,Altobelli GG,Calasanz MJ,Smeland EB,Aznar MA,Agirre X,Martin-Palanco V,Prosper F,Lossos IS,Martinez-Climent JA

doi

10.3324/haematol.2011.040568

subject

Has Abstract

pub_date

2011-07-01 00:00:00

pages

980-6

issue

7

eissn

0390-6078

issn

1592-8721

pii

haematol.2011.040568

journal_volume

96

pub_type

杂志文章
  • The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.

    abstract::We studied the impact of comorbidities on survival and evaluated the prognostic utility of comorbidity scores in MDS patients, who received best supportive care and were assessable according to the Charlson Comorbidity Index (CCI) and the Hematopoietic Stem Cell Transplantation Comorbidity Index (HCTCI): 171 patients ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2008.002063

    authors: Zipperer E,Pelz D,Nachtkamp K,Kuendgen A,Strupp C,Gattermann N,Haas R,Germing U

    更新日期:2009-05-01 00:00:00

  • Translocation t(9;14)(p13;q32) in cases of splenic marginal zone lymphoma.

    abstract::Translocation t(9;14)(p13;q32) involving PAX5 and IGH genes was first described in lymphoplasmacytic lymphoma. New data suggest that this translocation is not restricted to a specific morphologic subtype but occurs in other B-cell lymphomas. We present three cases with a diagnosis of splenic marginal zone lymphoma and...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Baró C,Salido M,Domingo A,Granada I,Colomo L,Serrano S,Solé F

    更新日期:2006-09-01 00:00:00

  • Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.

    abstract::Relapsed/refractory multiple myeloma represents a major challenge in multiple myeloma therapy. For patients with relapsed/refractory multiple myeloma, we developed a treatment schema of metronomically scheduled drug therapy. We identified 186 patients who had been treated with metronomic therapy between March 2004 and...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2013.085183

    authors: Papanikolaou X,Szymonifka J,Rosenthal A,Heuck CJ,Mitchell A,Johann D Jr,Keller J,Waheed S,Usmani SZ,Van Rhee F,Bailey C,Petty N,Hoering A,Crowley J,Barlogie B

    更新日期:2013-07-01 00:00:00

  • Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.

    abstract::In patients with low and intermediate risk myelodysplastic syndrome and deletion 5q (del(5q)) treated with lenalidomide, monitoring of cytogenetic response is mandatory, since patients without cytogenetic response have a significantly increased risk of progression. Therefore, we have reviewed cytogenetic data of 302 p...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2010.026658

    authors: Göhring G,Giagounidis A,Büsche G,Hofmann W,Kreipe HH,Fenaux P,Hellström-Lindberg E,Schlegelberger B

    更新日期:2011-02-01 00:00:00

  • Dendritic cells: specialized antigen presenting cells.

    abstract::Renewing interest in cancer immunotherapy reflects the excellent results that have been obtained in animal models and the promising results in early clinical trails with dendritic cell (DC) based approaches. The central role that DCs play in the initiation of an immune response raises the possibility of using them to ...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: Di Nicola M,Lemoli RM

    更新日期:2000-02-01 00:00:00

  • Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia.

    abstract::We quantified Wilm's tumor gene (WT1) using a real time quantitative polymerase chain reaction in 20 adult patients with acute lymphoblastic leukemia at presentation. A WT1 level greater than 906 (median value for the whole series) was a significant predictor of a poor disease-free and overall survival in uni- and mul...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Chiusa L,Francia di Celle P,Campisi P,Ceretto C,Marmont F,Pich A

    更新日期:2006-02-01 00:00:00

  • Atherogenic lipid stress induces platelet hyperactivity through CD36-mediated hyposensitivity to prostacyclin: the role of phosphodiesterase 3A.

    abstract::Prostacyclin (PGI2) controls platelet activation and thrombosis through a cyclic adenosine monophosphate (cAMP) signaling cascade. However, in patients with cardiovascular diseases this protective mechanism fails for reasons that are unclear. Using both pharmacological and genetic approaches we describe a mechanism by...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.213348

    authors: Berger M,Raslan Z,Aburima A,Magwenzi S,Wraith KS,Spurgeon BEJ,Hindle MS,Law R,Febbraio M,Naseem KM

    更新日期:2020-03-01 00:00:00

  • Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells.

    abstract::We report on a patient with relapsed chronic lymphocytic leukemia (CLL) treated with the novel mTOR inhibitor RAD001 within a phase II clinical trial. Although the patient initially responded to therapy, RAD001 was discontinued after 32 weeks due to progression and fludarabine-based chemotherapy was started. The patie...

    journal_title:Haematologica

    pub_type: 信件

    doi:10.3324/haematol.11155

    authors: Götze KS,Hoffmann D,Schätzl HM,Peschel C,Fend F,Decker T

    更新日期:2007-09-01 00:00:00

  • Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study.

    abstract::Double umbilical cord blood transplantation is increasingly applied in the treatment of adult patients with high-risk hematological malignancies and has been associated with improved engraftment as compared to that provided by single unit cord blood transplantation. The mechanism of improved engraftment is, however, s...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2014.106690

    authors: Somers JA,Braakman E,van der Holt B,Petersen EJ,Marijt EW,Huisman C,Sintnicolaas K,Oudshoorn M,Groenendijk-Sijnke ME,Brand A,Cornelissen JJ

    更新日期:2014-11-01 00:00:00

  • The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.

    abstract::Factor V Leiden (FVL) and prothrombin G20210A mutation (PTM) are the two most common genetic polymorphisms known to predispose to a first episode of venous thromboembolism (VTE). However, whether these thrombophilic abnormalities are also risk factors for recurrent VTE is unclear. We conducted a systematic review of p...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:10.3324/haematol.10234

    authors: Marchiori A,Mosena L,Prins MH,Prandoni P

    更新日期:2007-08-01 00:00:00

  • Primary lymphoma of the vagina. A case report.

    abstract::Primary vaginal non-Hodgkin lymphoma is really uncommon and may be misdiagnosed as inflammatory disease or solid cancer, so careful diagnostic procedures are needed, particularly as far as pathological and immunocytochemical evaluation is concerned. Most of these lymphomas present with follicular patterns and limited ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Lonardi F,Ferrari V,Pavanato G,Bonciarelli G,Jirillo A,Balli M

    更新日期:1994-03-01 00:00:00

  • A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.

    abstract::Sixteen patients with stage III multiple myeloma (MM) and a median age of 51 years were treated with autografting followed by reduced intensity conditioning allotransplantation (RICT). Nine patients are alive in remission at a median of 30 months after their transplants, one patient is alive in relapse and 6 patients ...

    journal_title:Haematologica

    pub_type: 临床试验,信件

    doi:

    authors: Carella AM,Beltrami G,Corsetti MT,Scalzulli P,Carella AM Jr,Musto P

    更新日期:2004-12-01 00:00:00

  • Factor X Shanghai and disruption of translocation to the endoplasmic reticulum.

    abstract:BACKGROUND AND OBJECTIVES:Most secreted proteins, including coagulation factor X (FX), are synthesized with a signal peptide, which is necessary for targeting the nascent polypeptide into the endoplasmic reticulum. Characterization of naturally occurring mutations may provide insights into the functional roles of the a...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Wang WB,Fu QH,Yin J,Wu WM,Ding QL,Zhou RF,Hu YQ,Wang XF,Wang ZY,Wang HL

    更新日期:2005-12-01 00:00:00

  • Detection of risk groups in myelodysplastic syndromes. A multicenter study.

    abstract:BACKGROUND AND OBJECTIVES:Myelodysplastic syndromes (MDS) comprise a group of heterogeneous hematologic disorders with risk of leukemic evolution (LE). The French-American-British (FAB) co-operative group classifies them into five morphologic entities and the International Prognostic Scoring System (IPSS) proposes four...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:

    authors: Belli C,Acevedo S,Bengio R,Arrossagaray G,Watman N,Rossi N,García J,Flores G,Goldztein S,Larripa I

    更新日期:2002-01-01 00:00:00

  • A novel transgenic mouse model produced from lentiviral germline integration for the study of beta-thalassemia gene therapy.

    abstract:BACKGROUND:beta-thalassemia is one of the most common genetic diseases in the world and requires extensive therapy. Lentiviral-mediated gene therapy has been successfully exploited in the treatment of beta-thalassemia and showed promise in clinical application. Using a human beta-globin transgenic mouse line in a beta-...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.12010

    authors: Li W,Xie S,Guo X,Gong X,Wang S,Lin D,Zhang J,Ren Z,Huang S,Zeng F,Zeng Y

    更新日期:2008-03-01 00:00:00

  • Immunoablation followed by autologous hematopoietic stem cell infusion for the treatment of severe autoimmune disease.

    abstract:BACKGROUND AND OBJECTIVES:The aim of this study was to evaluate the tolerability and effectiveness of a non-myeloablative conditioning regimen followed by autologous hematopoietic stem cell infusion for the treatment of severe autoimmune diseases. DESIGN AND METHODS:From 1996 patients with severe autoimmune disease no...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Rabusin M,Andolina M,Maximova N,Lepore L,Parco S,Tuveri G,Jankovic G

    更新日期:2000-11-01 00:00:00

  • CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients.

    abstract:BACKGROUND AND OBJECTIVES:Autologous stem cell transplantation (ASCT) is currently being evaluated as a therapy for patients with multiple sclerosis (MS). We report the results of a phase II trial to evaluate feasibility and toxicity of CD34+ selected ASCT (CD34+/ASCT) and treatment results at one year of follow-up. D...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:

    authors: Carreras E,Saiz A,Marín P,Martínez C,Rovira M,Villamor N,Aymerich M,Lozano M,Fernández-Avilés F,Urbano-Izpizua A,Montserrat E,Graus F

    更新日期:2003-03-01 00:00:00

  • Anticoagulation in the antiphospholipid syndrome.

    abstract::Our objectives were to evaluate thrombotic complications in patients with lupus anticoagulant fulfilling Sapporo criteria, anticoagulated with an intended INR 2.0-3.0 due to venous and arterial thrombosis. In our series standard anticoagulation was safe and efficacious in preventing recurrences in patients with system...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Casais P,Alberto MF,Gennari LC,Grosso SH,Meschengieser SS,Lazzari MA

    更新日期:2004-04-01 00:00:00

  • HLA-DRB1*15 and pediatric aplastic anemia.

    abstract::We report a positive association between HLA-DRB1*15 (p= 0.0002) in Turkish patients with pediatric severe aplastic anemia (SAA) and a paradoxically favorable influence of the susceptibility marker on the clinical response to immunosuppressive therapy. These findings point to an immune mechanism mediated by DRB1*15 in...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Oguz FS,Yalman N,Diler AS,Oguz R,Anak S,Dorak MT

    更新日期:2002-07-01 00:00:00

  • Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study.

    abstract::The mammalian target of rapamycin plays an important role in multiple myeloma. The allosteric mammalian target of rapamycin inhibitor everolimus has long been approved for immunosuppression and has shown activity in certain cancers. This investigator-initiated phase I trial explored the use of everolimus in relapsed a...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2014.116269

    authors: Günther A,Baumann P,Burger R,Kellner C,Klapper W,Schmidmaier R,Gramatzki M

    更新日期:2015-04-01 00:00:00

  • Cholesterol embolism of bone marrow clinically masquerading as systemic or metastatic tumor.

    abstract::A case of cholesterol embolism of bone marrow, concerning the pelvis and lumbar region and clinically masquerading as systemic disease or metastatic tumor, is reported in an 82-year-old man hospitalized for acute onset of reddish purple nodules on the legs and toes, intense myalgia and dorsal vertebral bone pain. The ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Muretto P,Carnevali A,Ansini AL

    更新日期:1991-05-01 00:00:00

  • A case of adult T cell leukemia and lymphoma in an Italian woman showing different malignant clones in tumor mass and in blood.

    abstract::HTLV-1 infections and their associated diseases are very rare in Italy, as well as in most parts of Europe, occurring prevalently in subjects related to endemic areas. The HTLV-1-associated leukemia/lymphoma, ATLL, is a very aggressive T-cell non-Hodgkin's lymphoma which can be difficult to recognize in non-endemic ar...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Menin C,Bulian P,Filippi F,Buttarello M,Casado C,Lopez-Galindez C,De Rossi A,Chieco-Bianchi L,Del Mistro A

    更新日期:2003-07-01 00:00:00

  • Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease.

    abstract:BACKGROUND:Chronic graft-versus-host disease is a common late complication of allogeneic hematopoietic stem cell transplantation. Corticosteroids are the standard initial treatment. Second-line treatment has not been well defined. We evaluated the effectiveness and safety of low doses of alemtuzumab plus low doses of r...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2011.054577

    authors: Gutiérrez-Aguirre CH,Cantú-Rodríguez OG,Borjas-Almaguer OD,González-Llano O,Jaime-Pérez JC,Solano-Genesta M,Gómez-Guijosa M,Mancias-Guerra C,Tarin L,Gómez-Almaguer D

    更新日期:2012-05-01 00:00:00

  • Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.

    abstract::Immunoparesis or suppression of polyclonal immunoglobulins is a very common condition in newly diagnosed myeloma patients. However, the recovery of polyclonal immunoglobulins in the setting of immune reconstitution after autologous stem cell transplantation and its effect on outcome has not yet been explored. We condu...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2016.158345

    authors: González-Calle V,Cerdá S,Labrador J,Sobejano E,González-Mena B,Aguilera C,Ocio EM,Vidriales MB,Puig N,Gutiérrez NC,García-Sanz R,Alonso JM,López R,Aguilar C,de Coca AG,Hernández R,Hernández JM,Escalante F,Mateos MV

    更新日期:2017-05-01 00:00:00

  • GFI1B controls its own expression binding to multiple sites.

    abstract:BACKGROUND:Transcription factors play essential roles in both normal and malignant hematopoiesis. This is the case for the growth factor independent 1b (GFI1B) transcription factor, which is required for erythroid and megakaryocytic differentiation and over-expressed in leukemic patients and cell lines. DESIGN AND MET...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2009.012351

    authors: Anguita E,Villegas A,Iborra F,Hernández A

    更新日期:2010-01-01 00:00:00

  • Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.

    abstract::The prognosis of patients with acute myeloid leukemia in whom primary treatment fails remains very poor. In order to improve such patients' outcome, we conducted a phase 2, prospective, multicenter trial to test the feasibility of a new sequential regimen, combining a short course of intensive chemotherapy and a reduc...

    journal_title:Haematologica

    pub_type: 杂志文章,多中心研究

    doi:10.3324/haematol.2016.150326

    authors: Mohty M,Malard F,Blaise D,Milpied N,Socié G,Huynh A,Reman O,Yakoub-Agha I,Furst S,Guillaume T,Tabrizi R,Vigouroux S,Peterlin P,El-Cheikh J,Moreau P,Labopin M,Chevallier P

    更新日期:2017-01-01 00:00:00

  • Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies.

    abstract::We conducted a phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with relapsed, refractory myeloid leukemias. Twenty-eight patients received the construct intravenously at four dose levels (12, 18, 28 and 40 mg/m(2) per course) i...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2012.071092

    authors: Borthakur G,Rosenblum MG,Talpaz M,Daver N,Ravandi F,Faderl S,Freireich EJ,Kadia T,Garcia-Manero G,Kantarjian H,Cortes JE

    更新日期:2013-02-01 00:00:00

  • Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinic

    abstract:BACKGROUND AND OBJECTIVE:In a prior study, primary resistant acute lymphoblastic leukemia (RES-ALL) was observed in 11 of 176 (6%) adult patients treated with a four drug regimen (IVAP), its incidence being higher in T-cell or Philadelphia (Ph) chromosome/BCR-ABL rearrangement positive ALL cases with a blast cell count...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Bassan R,Pogliani E,Lerede T,Fabris P,Rossi G,Morandi S,Casula P,Lambertenghi-Deliliers G,Vespignani M,Izzi T,Coser P,Corneo G,Barbui T

    更新日期:1999-12-01 00:00:00

  • Development of a coordinated allo T cell and auto B cell response against autosomal PTK2B after allogeneic hematopoietic stem cell transplantation.

    abstract::It is well known that allo-reactive T cells play a crucial role in graft-versus-leukemia and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation (alloSCT). Allo-reactive CD4(+) T cells can mediate direct cytolysis, but may also stimulate production of IgG antibodies as helper cells. Immu...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2013.086652

    authors: Kremer AN,van der Griendt JC,van der Meijden ED,Honders MW,Ayoglu B,Schwenk JM,Nilsson P,Falkenburg JH,Griffioen M

    更新日期:2014-02-01 00:00:00

  • ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.

    abstract::Previous studies identified the Ser/Thr protein kinase, AKT, as a therapeutic target in thrombo-inflammatory diseases. Here we report that specific inhibition of AKT with ARQ 092, an orally-available AKT inhibitor currently in phase Ib clinical trials as an anti-cancer drug, attenuates the adhesive function of neutrop...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2016.151159

    authors: Kim K,Li J,Barazia A,Tseng A,Youn SW,Abbadessa G,Yu Y,Schwartz B,Andrews RK,Gordeuk VR,Cho J

    更新日期:2017-02-01 00:00:00